logo-loader

ChromaDex starts enrolment for NIAGEN study

Last updated: 00:49 23 Feb 2016 AEDT, First published: 19:49 22 Feb 2016 AEDT

08
Mooove aside milk. NIAGEN recreates a naturally occurring vitamin B3 metabolite found in the dairy product

Chromadex (OTC:CDXC), a developer of wellness and dietary products, announced the enrollment of the first patients for a collaborative human clinical study of NIAGEN.

NIAGEN is the first and only commercially available form of nicotinamide riboside (NR), a naturally occurring vitamin B3 metabolite found in milk.

Frank Jaksch, founder and chief executive, said: “The human study is designed to provide a better understand on how NR can help people optimize their physical and metabolic functions.”

The project being conducted at the University of Copenhagen will be a placebo controlled, double-blind, randomized study of 40 obese healthy men.

It will assess the potential benefits of the supplement over the course of 12 weeks, the company said.

This new study will build upon the first successful clinical trial conducted in 2015 which demonstrated that a single dose of NIAGEN can safely elevate the co-enzyme NAD+ in the blood by as much as 2.7 times.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

10 hours, 16 minutes ago